Skip to main content
Terug
ALLO logo

Allogene Therapeutics, Inc.

Datakwaliteit: 100%
ALLO
NASDAQ Healthcare Biotechnology
€ 2,44
▲ € 0,37 (17,87%)
Marktkapitalisatie: 548,34M
Dagbereik
€ 2,13 € 2,60
52-Weeksbereik
€ 0,86 € 2,80
Volume
11.639.138
50D / 200D Gem.
€ 2,01 / € 1,45
Vorige Slotkoers
€ 2,07

Koershistorie

Financiële Trends

Sectorvergelijking

vs Healthcare sector mediaan (626 peers)

Metriek Aandeel Sector Mediaan
P/E -2,9 0,4
P/B 1,9 2,9
ROE % -53,4 3,8
Net Margin % 3,9
Rev Growth 5Y % 10,0
D/E 0,3 0,2

Koersdoel Analisten

Hold
€ 29,00 +1088.5%
Low: € 7,00 High: € 55,00
Forward WPA
-€ 0,80
Omzet Sch.
17000

Winstschattingen

Periode WPA Sch. Omzet Sch. Analisten
FY2030 € 0,90
€ 0,90 – € 0,90
650 M 4
FY2029 -€ 0,03
-€ 0,03 – -€ 0,03
340 M 4
FY2028 -€ 0,70
-€ 1,02 – -€ 0,27
110 M 10

Belangrijkste Punten

Debt/Equity of 0,26 — conservative balance sheet
Negative free cash flow of -149,63M
PEG of 0,05 suggests growth is underpriced

Groei

Revenue Growth (5Y)
N/A
Revenue (1Y)-100,00%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Kwaliteit

Return on Equity
-53,42%
ROIC-42,22%
Net MarginN/A
Op. MarginN/A

Veiligheid

Debt / Equity
0,26
Current Ratio7,93
Interest Coverage-192,50

Waardering

P/E Ratio
-2,87
P/B Ratio1,87
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -100,00% Revenue Growth (3Y) N/A
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) N/A Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 0,0 Net Income (TTM) -190,89M
ROE -53,42% ROA -45,90%
Gross Margin N/A Operating Margin N/A
Net Margin N/A Free Cash Flow (TTM) -149,63M
ROIC -42,22% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,26 Current Ratio 7,93
Interest Coverage -192,50 Dividend Yield 0,00%
Valuation
P/E Ratio -2,87 P/B Ratio 1,87
P/S Ratio N/A PEG Ratio 0,05
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 548,34M Enterprise Value 571,70M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 0,0 22.000,0 95.000,0 156.000,0 114,09M
Net Income -190,89M -257,59M -327,27M -340,41M -182,05M
EPS (Diluted) -0,87 -1,32 -2,09 -2,38 -1,34
Gross Profit -12,36M 22.000,0 95.000,0 -14,14M 114,09M
Operating Income -206,93M -273,20M -327,74M -335,54M -180,19M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 415,91M 548,71M 642,84M 821,58M 1,05B
Total Liabilities 123,36M 126,53M 130,60M 154,70M 125,63M
Shareholders' Equity 292,54M 422,18M 512,23M 666,88M 925,20M
Total Debt 75,05M 90,76M 95,12M 101,12M 73,13M
Cash & Equivalents 51,69M 75,22M 83,16M 61,90M 173,31M
Current Assets 257,75M 303,39M 459,12M 528,82M 471,32M
Current Liabilities 32,51M 35,52M 37,08M 53,73M 47,91M